We therefore hypothesize that the mitochondrial localization of NLGN2 is instrumental to its prognostic role in breast cancer, and should be explored further, especially from the perspectives of immunoregulation and immunotherapy. This evidence concerns the gene NLGN2 and breast carcinoma.